Fulcrum Therapeutics Inc (FULC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $283.38M
Last updated: Nov 17, 2026 at 4:10 PM ET
Fulcrum Therapeutics Inc (FULC) Statistics
Fulcrum Therapeutics (FULC) has a market cap of $283.38M and an enterprise value of $166.97M. Its share count is up 21.92% from a year earlier. It holds $116.41M more cash than debt, 41.08% of its market cap.
Total Valuation
Enterprise value is 41.08% below the market cap, as cash exceeds debt.
| Market Cap | $283.38M |
|---|---|
| Enterprise Value | $166.97M |
| Latest price (Nov 17, 2026) | $3.75 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 56.65% over 52 weeks and trades 0.54% above its 50-day average.
| Beta (1Y) | 0.53 |
|---|---|
| 52-Week Change | -56.65% |
| 1-Month Change | +1.35% |
| 3-Month Change | -4.09% |
| 6-Month Change | -36.55% |
| 5-Year Change | -83.24% |
| Total Return (1Y) | -56.65% |
| Total Return (3Y CAGR) | -3.32% |
| Total Return (5Y CAGR) | -26.26% |
| Return vs SPY (1Y) | -73.02% |
| Max Drawdown (1Y) | -78.49% |
| Max Drawdown (3Y) | -79.08% |
| Sharpe Ratio (1Y) | -0.95 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $3.73 |
| 200-Day Average | $5.45 |
| 52-Week Range | $2.83 to $15.74 |
| RSI (14 Days) | 52.7 |
| Average Volume (20 Days) | 1.35M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 36.19x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 36.19x |
|---|---|
| Quick Ratio | 36.19x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -25.28% over the last 12 months, against a 5-year average of -32.06%.
| Return on Equity (ROE) | -25.28% |
|---|---|
| Return on Assets (ROA) | -24.56% |
| ROE (5Y Average) | -32.06% |
| ROA (5Y Average) | -28.96% |
| ROIC (5Y Average) | -19.19% |
Scores
FULC has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | $300.00K |
| Operating Income | -$88.05M |
| Pretax Income | -$76.34M |
| Net Income | -$76.34M |
| Reported EPS (TTM) | -$0.96 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 97.18% of the $310.81M in total assets.
| Cash and Equivalents | $116.41M |
|---|---|
| Total Debt | $0 |
| Net Cash | $116.41M |
| Net Cash Per Share | $1.53 |
| Working Capital | $302.21M |
| Shareholder Equity | $302.03M |
| Book Value Per Share | $3.96 |
| Total Assets | $310.81M |
| Total Liabilities | $8.78M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$64.97M |
|---|---|
| FCF Per Share | -$0.85 |
| Depreciation and Amortization | $3.49M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +20.38% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +20.38% |
Dividends and Yields
FULC does not pay a dividend.
| Buyback Yield | -58.89% |
|---|---|
| Shareholder Yield | -58.89% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About FULC
What is FULC's market cap?
Fulcrum Therapeutics has a market cap of $283.38M. Its enterprise value, which adds debt and subtracts cash, is $166.97M.
How many shares of FULC are outstanding?
Fulcrum Therapeutics has 76.32M shares outstanding. The count is up 21.92% from a year earlier.
Does FULC pay a dividend?
No. Fulcrum Therapeutics does not pay a dividend.
How much debt does FULC have?
Fulcrum Therapeutics has $0 of total debt and $116.41M of cash and equivalents, a net cash position of $116.41M.
FULC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors